American Journal of Gastroenterology最新文献

{"title":"High Rates of Seroprotection for Measles in Pediatric Patients With Inflammatory Bowel Disease.","authors":"Freddy Caldera, Mary S Hayney, Jennifer A Strople, Arthur J Kastl, Jeremy Adler, Margie Boccieri, Xian Zhang, Millie D Long, Michael D Kappelman","doi":"10.14309/ajg.0000000000004050","DOIUrl":"10.14309/ajg.0000000000004050","url":null,"abstract":"<p><strong>Introduction: </strong>The ongoing US measles outbreak raises concerns for immunosuppressed children with inflammatory bowel disease (IBD).</p><p><strong>Methods: </strong>We evaluated measles seroprotection in pediatric patients with IBD using a high-sensitivity ELISA (Zeus) compared with a standard commercial assay.</p><p><strong>Results: </strong>Among 176 patients, 173 (98%) were seropositive despite 87% being on immunosuppressive therapy. In comparison, only 163 (93%) were seropositive by commercial assay, resulting in a negative predictive value of 23%.</p><p><strong>Discussion: </strong>Children with IBD have high measles seroprotection. A negative commercial result should not be interpreted as lack of seroprotection, highlighting the need for more accurate assays.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2581-2584"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147969618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.","authors":"Franco Scaldaferri, Federica Di Vincenzo, Marina Aloi, Marta Ascolani, Paola Balestrieri, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Emma Calabrese, Rosanna Cannatelli, Flavio Caprioli, Marica Cappello, Michele Cicala, Ferdinando D'Amico, Silvio Danese, Alice De Bernardi, Francesca Romana De Filippo, Federico Desideri, Dhanai Di Paolo, Antonio Di Sario, Massimo Claudio Fantini, Concetta Ferracane, Stefano Festa, Gionata Fiorino, Roberto Gabbiadini, Andrea Geccherle, Viviana Gerardi, Emiliano Giangreco, Antonietta Gerarda Gravina, Lucrezia Laterza, Loris Riccardo Lopetuso, Irene Marafini, Mauro Mastronardi, Marco Mendolaro, Manuela Merli, Giammarco Mocci, Sara Onali, Maria Francesca Onidi, Luca Pastorelli, Alessandra Piagnani, Maria Beatrice Principi, Daniela Pugliese, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Fabrizio Santagata, Edoardo Vincenzo Savarino, Rocco Spagnuolo, Antonio Tursi, Alba Panarese, Silvia Mazzuoli, Angela Variola, Chiara Viganò, Alessandro Armuzzi","doi":"10.14309/ajg.0000000000003969","DOIUrl":"10.14309/ajg.0000000000003969","url":null,"abstract":"<p><strong>Introduction: </strong>To assess the effectiveness and safety of Risankizumab (RZB) in a large, nationwide real-world cohort of patients with Crohn's disease (CD).</p><p><strong>Methods: </strong>We conducted a multicenter, retrospective observational cohort of adults initiating RZB with assessments at weeks 12, 26, and 52. Coprimary end points were (i) week-12 steroid-free clinical remission (SFCR) (Harvey-Bradshaw Index <5 in the absence of systemic corticosteroids or budesonide) and (ii) week-52 endoscopic remission (Simple Endoscopic Score-CD 0-2 or Rutgeerts i0-i1 postoperatively). The main effectiveness analysis was as-observed; a preplanned sensitivity analysis included patients expected to reach week-52 before database lock and applied nonresponder imputation.</p><p><strong>Results: </strong>We included 520 patients, 45.0% failed ≥3 and 54.8% were ustekinumab (UST)-exposed. At week 12, clinical response was 76.5% and 60.8% achieved SFCR. By week 52, SFCR was 65.6%; endoscopic remission occurred in 37.5%, whereas radiologic remission and transmural healing were 24.6% and 9.8%, respectively. UST-naïve patients showed significantly superior early clinical outcomes (week-12 SFCR: 69.8% vs 53.3%) and a higher rate of endoscopic remission at week 52 (56.5% vs 28.6%) compared with UST-exposed patients. Notably, week-52 effectiveness was comparable between patients with 2 and those with ≥3 previous failures. Extraintestinal manifestations decreased over time, whereas perianal disease improved modestly. In the sensitivity cohort (N = 213), SFCR was 47% at week-52. RZB was well-tolerated with no new safety signals identified.</p><p><strong>Discussion: </strong>In a large, refractory, real-world CD population, RZB induced rapid and sustained favorable clinical, endoscopic, and radiologic outcomes. Importantly, one-year effectiveness was similar in patients with 2, and ≥3 previous failures, supporting RZB as a valuable option for a refractory population.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2492-2503"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13629653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease.","authors":"Kate L Karlin, Ella H Gilbert, Francesca Lim, Alice A Agyekum, Jeong Yun Yang, Adam S Faye, Amit Patel, Chin Hur, David A Leiman","doi":"10.14309/ajg.0000000000003943","DOIUrl":"10.14309/ajg.0000000000003943","url":null,"abstract":"<p><strong>Introduction: </strong>Potassium competitive acid blockers (PCABs) are superior to proton pump inhibitors (PPIs) for healing of Los Angeles (LA) class C/D erosive esophagitis and are approved for nonerosive gastroesophageal reflux disease (GERD) given their efficacy measured by heartburn-free days. However, they are more expensive than PPIs. We estimated the cost-effectiveness of PCABs compared with PPIs for the management of GERD.</p><p><strong>Methods: </strong>A decision tree was constructed for the base case of a patient with GERD. We tested scenarios in which nonerosive reflux disease, LA A/B, or LA C/D esophagitis was present, comparing PCABs with PPIs as first-line therapy, including step up therapy and/or class switching if symptoms persisted. Using publicly available cost estimates, quality-adjusted life years (QALYs) were compared using a willingness-to-pay threshold of $100,000/QALY from a societal perspective at 6 months.</p><p><strong>Results: </strong>The cost of PCABs for GERD was $3,240 more than PPIs, with an incremental cost-effectiveness ratio of $144,208/QALY. When evaluating GERD phenotypes separately, the incremental cost-effectiveness ratio was consistently over our willingness-to-pay threshold. One-way analyses showed the most influential parameters were PCAB cost and efficacy for heartburn-free days. Probabilistic sensitivity analysis favored PPIs 71.7% out of 100,000 iterations. Reducing one-week costs to below $91 would make PCABs a cost effective first-line strategy across all GERD phenotypes.</p><p><strong>Discussion: </strong>Despite PCAB efficacy, PPIs are a cost-effective strategy for GERD treatment, and can be positioned ahead of PCAB escalation on this basis. Reducing PCAB costs or accepting a higher willingness-to-pay threshold would influence this finding, although PCABs may be favored in some current situations as evidenced by probabilistic sensitivity results.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2401-2410"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autonomic Dysfunction in Gastroduodenal Disorders Evaluated Through Multimodal Non-Invasive Physiological Testing.","authors":"Chris Varghese, Wendy Zhou, Armen Gharibans, Gabriel Schamberg, Sibylle Van Hove, John Clarke, Greg O'Grady, Leila Neshatian, Linda Nguyen","doi":"10.14309/ajg.0000000000003958","DOIUrl":"10.14309/ajg.0000000000003958","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic gastroduodenal disorders are highly prevalent and encompass heterogeneous pathophysiology. Autonomic dysfunction may contribute, but its relative contribution to disease pathophysiology and symptoms is unclear. This study aimed to clarify the contributions of autonomic dysfunction in gastroduodenal disorders and symptom associations using multimodal testing, hypothesizing that distinct disorder subgroups would be revealed.</p><p><strong>Methods: </strong>This prospective observational cohort study included 80 patients with chronic gastroduodenal symptoms. Participants underwent expert clinician-led autonomic evaluation, body surface gastric mapping (BSGM; Gastric Alimetry, New Zealand), and gastric emptying scintigraphy testing. BSGM phenotyping, gastric emptying cutoffs, and autonomic criteria followed standard criteria.</p><p><strong>Results: </strong>Gastroparesis was diagnosed in 27 (33.8%) patients. Autonomic dysfunction was present in 21 (26.3%) patients, and abnormal BSGM in 20 (25%). Autonomic dysfunction and abnormal BSGM were both more prevalent in gastroparesis (51.9% vs 13.2%, P = 0.001; and 44.4% vs 15.1%, P = 0.005, respectively). However, these diagnoses tended not to overlap, with patients having autonomic dysfunction generally exhibiting normal BSGM tests. Autonomic dysfunction independently predicted delayed gastric emptying (OR 13.8, P < 0.001) and was associated with earlier meal responses (higher meal response ratio, P = 0.04) and worse postprandial distress symptoms ( P < 0.05).</p><p><strong>Discussion: </strong>Autonomic dysfunction independently predicted delayed gastric emptying and revealed a gastroparesis mechanism distinct from gastric myoelectrical impairment. Autonomic dysfunction altered the postprandial gastric motor response and was associated with a greater symptom burden. Multimodal physiological testing including autonomic profiling reveals distinct mechanistic subgroups in patients with chronic gastroduodenal symptoms.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2522-2531"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146163630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease.","authors":"Emily C L Wong, Vipul Jairath, Parambir S Dulai, John K Marshall, Christopher Ma, Walter Reinisch, Neeraj Narula","doi":"10.14309/ajg.0000000000003940","DOIUrl":"10.14309/ajg.0000000000003940","url":null,"abstract":"<p><strong>Introduction: </strong>Rapid symptom control is critical in managing ulcerative colitis (UC), especially in patients with severe disease. Although multiple advanced therapies are approved for moderate to severe UC, data comparing their speed of onset are limited. We compared the onset and induction efficacy of advanced therapies for UC among biologic-naïve patients with severe endoscopic disease (Mayo endoscopic score [MES] of 3) and explored differential responses in patients with moderate (MES 2) vs severe endoscopic disease.</p><p><strong>Methods: </strong>This was a post hoc analysis using individual participant-level data from 11 randomized controlled trials. Biologic-naïve patients with MES 3 disease receiving standard induction regimens of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, mirikizumab, tofacitinib, or upadacitinib were included. The primary outcome was early PRO-2 response, defined as ≥50% reduction in stool frequency and rectal bleeding scores at 2 weeks postbaseline. Secondary outcomes included postinduction clinical remission and PRO-2 remission. Logistic regression models adjusted for baseline covariates were used.</p><p><strong>Results: </strong>A total of 1,781 biologic-naïve patients with MES 3 disease were included. Infliximab (35.1%) and upadacitinib (32.4%) demonstrated the highest early PRO-2 response rates. Compared with placebo, the highest odds of response were observed with upadacitinib (adjusted odds ratio: 6.38 [95% CI: 2.11-19.23], P = 0.001) and infliximab (adjusted odds ratio 4.49 [95% CI: 2.05-9.85], P < 0.001). At postinduction, infliximab (72.2%) and upadacitinib (59.5%) again demonstrated superior PRO-2 response rates. In comparison to MES 2 patients, those with MES 3 had reduced odds of early and postinduction response for several therapies, particularly ustekinumab, tofacitinib, vedolizumab, and mirikizumab.</p><p><strong>Discussion: </strong>Among biologic-naïve UC patients with severe endoscopic disease, infliximab and upadacitinib had the highest rates of week 2 and postinduction PRO-2 response. Baseline disease activity may help to better inform treatment choices.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2504-2512"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histogenetic Classification Predicts Outcomes in 130 Adults With Chronic Intestinal Pseudo-Obstruction.","authors":"Minh-Chau Ta, Dominique Cazals-Hatem, Lore Billiauws, Aurélien Amiot, Marc Bellaiche, Dominique Berrebi, Benoit Coffin, Olivier Corcos, Emmanuelle Ecochard-Dugelay, Olivier Goulet, Florence Lacaille, Cécile Lambe, Yann Nadjar, John Rendu, Cécile Talbotec, Fabienne Charbit-Henrion, Francisca Joly","doi":"10.14309/ajg.0000000000003980","DOIUrl":"10.14309/ajg.0000000000003980","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic intestinal pseudo-obstruction (CIPO) is a rare, heterogeneous disorder associated with severe morbidity. Genetic variants and histopathological lesions have been described, but their combined evaluation has rarely been assessed in adult CIPO cohorts. This study aimed to evaluate the contribution of integrated genetic and histological analyses in adults with CIPO.</p><p><strong>Methods: </strong>We conducted a retrospective observational study of adults with CIPO followed at a national tertiary referral center. Patients with CIPO underwent genomic profiling, including next-generation sequencing (NGS) panel, long-range polymerase chain reaction (PCR), whole-exome, and whole-genome sequencing. Centralized histological analysis of full-thickness bowel biopsies and resections was integrated with genomic data to assess their combined impact on disease outcomes.</p><p><strong>Results: </strong>The cohort included 130 patients (75 females, 55 males, aged 19-74 years), followed for up to 64 years. Genetic and histological analyses characterized 82% of the patients (genetic diagnosis: n = 65/112, 58%; histological diagnosis: n = 73/96, 76%), allowing the classification of patients into 6 groups: monogenic myopathy (n = 42), mitochondriopathy (n = 19), unspecified myopathy (n = 26), autoimmune myopathy (n = 8), neuropathy (n = 9), and others (n = 26). Survival and postoperative outcomes differed across groups. In this cohort, patients with monogenic myopathy had the most favorable long-term survival (adjusted hazard ratio: 0.06, 95% CI: 0.01-0.42; P = 0.004) and higher rates of improvement after bowel resection compared with other patients.</p><p><strong>Discussion: </strong>Integrated genetic and histological evaluation informed etiological classification in adults with CIPO and may aid clinical decision-making.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2532-2544"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13629656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Neoplasia Rates in Li-Fraumeni Syndrome.","authors":"Sophia R Spiegel, Caitlin Orr, Nicolas U Edgar, Sophie R Cahill, Anh N Le, Madeline Good, Jo Lyman, Soren Feola, Casey Mehrhoff, Anne Naumer, Jennie Vagher, Isabel Anez, Nathaniel Frucht, Luke D Maese, Judy E Garber, Asaf Maoz, Bryson W Katona, Suzanne P MacFarland, Kara N Maxwell","doi":"10.14309/ajg.0000000000003976","DOIUrl":"10.14309/ajg.0000000000003976","url":null,"abstract":"<p><strong>Introduction: </strong>Individuals with Li-Fraumeni syndrome (LFS), a cancer predisposition syndrome caused by TP53 pathogenic germline variants (PGV), have an increased risk of colorectal cancer (CRC). However, limited data exist on colonoscopy metrics, including total neoplasia detection rates, in patients with LFS.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of colorectal neoplasia incidence and characteristics in 663 individuals with LFS. We determined total neoplasia detection rate, adenoma detection rate (ADR), advanced ADR, serrated lesion detection rate (SDR), and CRC detection rate, stratified by age, sex, and PGV subtype, in 311 surveillance colonoscopies from 206 adults performed January 2019 to August 2024.</p><p><strong>Results: </strong>CRC was reported in 4.5% of 663 adults and 0.8% of 124 pediatric patients with LFS. Among 206 adults undergoing colonoscopy, total neoplasia detection rate, ADR, SDR, advanced precancerous polyp detection rate, and CRC detection rate were 37%, 27%, 9.3%, 4.5%, and 0.64%, respectively. Detection rates were similar between loss of function and hypomorphic PGVs. Adults aged 45-75 had higher total neoplasia detection rate, ADR, advanced ADR, SDR, and CRC detection rate than those aged 25-45. Male sex was associated with increased total neoplasia detection rate (53.7% vs 30.7%, P = 0.0004), ADR (41.2% vs 22.1%, P = 0.0013), and advanced ADR (7.5% vs 1.3%, P = 0.0105).</p><p><strong>Discussion: </strong>Patients with LFS have comparable ADR and higher SDR with average-risk adults despite earlier, more frequent surveillance, irrespective of TP53 PGV subtype. Our data support current recommendations for earlier and more frequent colonoscopy surveillance than average-risk guidelines, across LFS phenotypes.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2434-2440"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic Encephalopathy is the Key Driver of Symptom Burden in a Longitudinal Cohort of Patients With Advanced Chronic Liver Disease: PAL-LIVER Substudy.","authors":"Elliot B Tapper, Christopher D Woodrell, Mina Rakoski, Ronald Huang, Andrzej S Kosinski, Manisha Verma","doi":"10.14309/ajg.0000000000003964","DOIUrl":"10.14309/ajg.0000000000003964","url":null,"abstract":"<p><strong>Introduction: </strong>Cirrhosis is a chronic illness with high morbidity, marked by persistent physical and psychological symptoms that affect patients and their caregivers. Longitudinal data on symptom trajectories and their determinants, particularly hepatic encephalopathy (HE), are limited.</p><p><strong>Methods: </strong>We conducted a secondary analysis of palliative care for liver diseases (PAL-LIVER), a 19-site cluster-randomized trial comparing hepatologist-led and consultative palliative care for patients with decompensated cirrhosis and/or hepatocellular carcinoma. Patients and caregivers completed assessments at baseline and multiple intervals up to 12 months (patients: modified ESAS-13, Patient Health Questionnaire-9, Distress Thermometer; caregivers: Zarit Burden Interview-12). Latent class growth analysis identified subgroups with persistently high or low burden for each symptom. Multivariable models evaluated associations between HE and symptom/caregiver burden, adjusting for demographics, disease severity, and comorbidities.</p><p><strong>Results: </strong>Nine hundred thirty-five patients were enrolled, 823 with HE information, 368 of whom had HE at baseline. Symptom burden trajectories remained stable over 12 months. HE was the primary independent predictor of high overall symptom burden (Edmonton Symptom Assessment Scale odds ratio [OR] 1.83, 95% CI 1.38-2.41), depression (Patient Health Questionnaire-9 OR 1.93, 95% CI 1.44-2.60), and greater caregiver burden (Zarit Burden Interview-12 OR 1.53, 95% CI 1.02-2.30). Alcohol-related liver disease and female sex were also associated with higher symptom burden. Caregiver burden remained generally low and stable.</p><p><strong>Discussion: </strong>Symptom burden in cirrhosis is generally stable but remain high among certain subgroups, especially those with HE. HE is the strongest and most consistent determinant of physical, psychological, and caregiver burden in cirrhosis. These findings highlight the urgent need for novel, HE-targeted interventions and comprehensive symptom management strategies particularly for women and those with alcohol-related liver disease.</p>","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"2441-2448"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Choudhuri.","authors":"Uma Mahadevan, Michelle Segovia, Joseph Wu, Ivana Vranic, Annette Diehl, Arthur Kavanaugh","doi":"10.14309/ajg.0000000000004095","DOIUrl":"10.14309/ajg.0000000000004095","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"e99"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13629647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148676864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor.","authors":"Fang Jiang, Bingli Guo, Dan Zhao","doi":"10.14309/ajg.0000000000004102","DOIUrl":"10.14309/ajg.0000000000004102","url":null,"abstract":"","PeriodicalId":7608,"journal":{"name":"American Journal of Gastroenterology","volume":" ","pages":"e101-e102"},"PeriodicalIF":8.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}